A community for people who want to remain as healthy as possible as we age.

Lilly says drug slows Alzheimer's in patients with mild disease

(Reuters) Patients with mild Alzheimer's disease who took Eli Lilly and Co's experimental drug solanezumab early in the course of their disease preserved more of their cognitive and functional ability, according to new Lilly data released on Wednesday…
In 2012, the original 18-month studies of solanezumab, called Expedition and Expedition 2, each included about 1,000 patients with mild to moderate disease. The drug failed to slow cognitive declines or loss of abilities of daily living for the entire patient population.
But when Lilly analyzed results only for mild patients, the data suggested solanezumab caused a significant 34 percent slowdown in mental decline and an 18 percent slowdown in loss of functional abilities compared to placebo, researchers said.
Community: There are many practical things we can do to prevent, delay, or minimize the severity of cognitive decline.
[Click the title, above, to post a comment.]

0 comments:

Post a Comment

Please do not give advice. We can best help each other by telling what works for us, not what we think someone else should do.